Next Article in Journal
Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia
Next Article in Special Issue
Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
Previous Article in Journal
Supporting Immunization Uptake during a Pandemic, Using Remote Phone Call Intervention among Babies Discharged from a Special Neonatal Care Unit (SNCU) in South India
Previous Article in Special Issue
Autochthonous Outbreak of SARS-CoV-2 Omicron Variant in Booster-Vaccinated (3 Doses) Healthcare Workers in Southern Italy: Just the Tip of the Iceberg?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 4
10.3390/vaccines10040508
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant

by
Olaf-Oliver Wolz
1,*,
Sarah-Katharina Kays
2,
Helga Junker
2,
Sven D. Koch
1,
Philipp Mann
2,
Gianluca Quintini
1,
Philipp von Eisenhart-Rothe
1 and
Lidia Oostvogels
2
1
CureVac AG, Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany
2
CureVac AG, Schumannstr. 27, 60325 Frankfurt, Germany
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(4), 508; https://doi.org/10.3390/vaccines10040508
Submission received: 22 February 2022 / Revised: 19 March 2022 / Accepted: 23 March 2022 / Published: 25 March 2022
(This article belongs to the Special Issue SARS-CoV-2 Variants Research and Ending the COVID-19 Pandemic)
Browse Figure
Review Reports Versions Notes

Abstract

A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in adults aged 18–60 and >60 years in a phase 2a clinical study. In the present study, we report the neutralizing antibody responses to a wild-type and a variant of concern, Delta, after a third dose of the vaccine on day (D)57 and D180. Neutralization activity was assessed using a microneutralization assay. Comparable levels of neutralizing antibodies against the wild-type and Delta were induced. These were higher than those observed after the first two doses, irrespective of age or pre-SARS-CoV-2-exposure status, indicating that the first two doses induced immune memory. Four weeks after the third dose on D180, the neutralizing titers for wild-type and Delta were two-fold higher in younger participants than in older participants; seroconversion rates were 100% for wild-type and Delta in the younger group and for Delta in the older group. A third CVnCoV dose induced similar levels of neutralizing responses against wild-type virus and the Delta variant in both naïve and pre-exposed participants, aligning with current knowledge from licensed COVID-19 vaccines that a third dose is beneficial against SARS-CoV-2 variants.
Keywords: SARS-CoV-2; COVID-19 vaccine; neutralizing antibodies; delta variant SARS-CoV-2; COVID-19 vaccine; neutralizing antibodies; delta variant

Share and Cite

MDPI and ACS Style

Wolz, O.-O.; Kays, S.-K.; Junker, H.; Koch, S.D.; Mann, P.; Quintini, G.; von Eisenhart-Rothe, P.; Oostvogels, L. A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines 2022, 10, 508. https://doi.org/10.3390/vaccines10040508

AMA Style

Wolz O-O, Kays S-K, Junker H, Koch SD, Mann P, Quintini G, von Eisenhart-Rothe P, Oostvogels L. A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines. 2022; 10(4):508. https://doi.org/10.3390/vaccines10040508

Chicago/Turabian Style

Wolz, Olaf-Oliver, Sarah-Katharina Kays, Helga Junker, Sven D. Koch, Philipp Mann, Gianluca Quintini, Philipp von Eisenhart-Rothe, and Lidia Oostvogels. 2022. "A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant" Vaccines 10, no. 4: 508. https://doi.org/10.3390/vaccines10040508

APA Style

Wolz, O.-O., Kays, S.-K., Junker, H., Koch, S. D., Mann, P., Quintini, G., von Eisenhart-Rothe, P., & Oostvogels, L. (2022). A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines, 10(4), 508. https://doi.org/10.3390/vaccines10040508

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop